Lukas Manuel Dunkl

Biochemistry, Genetics and Molecular Biology · Life Sciences

2h-index209citations23works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(22), Melanoma and MAPK Pathways(19), interferon and immune responses(6), Synthesis and biological activity(4), Colorectal Cancer Treatments and Studies(4)

Publications23 total

Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 5 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Data from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 5 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Data from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
Molecular Cancer Research·2020
Cdk1 Controls Global Epigenetic Landscape in Embryonic Stem Cells
Molecular Cell·2020· 117 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Hengyu Lu(22), Chen Liu(22), Roberto Velazquez(22), Malika Kazic-Legueux(22), Anne Haberkorn(22), Éric Billy(22), Eusebio Manchado(22), Saskia M. Brachmann(22), Susan E. Moody(22), Jeffrey A. Engelman(22), Peter S. Hammerman(22), Giordano Caponigro(22), Morvarid Mohseni(22), Huai-Xiang Hao(21), Hongyun Wang(20), Hongyun Wang(2), Wojciech Michowski(1), Joel M. Chick(1), Chen Chu(1), Aleksandra Kołodziejczyk(1)